{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.24"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"Determined as the median of the marginal posterior distribution using data from all available patients","groups":[{"description":"Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.\n\nRituximab: 375 mg/m2 I.V. on Day 1 of each cycle\n\nBendamustine: 90 mg/m2 I.V. on Day 1 and 2 of each cycle\n\nVincristine sulfate liposome injection: Dose per dose escalation protocol, I.V. on Day 2 of each cycle","id":"OG000","title":"Dose-escalation Cohort"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Up to 6 cycles of treatment (approximately 6 months)","title":"Maximum Tolerated Dose","type":"PRIMARY","unitOfMeasure":"mg/m^2"}